Regular Hours
|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
| Valuation Estimation |
|
EPS (Current/Estimated)
6.96/2.74
|
|
Enterprise Value
45.79B
|
| Balance Sheet |
|
Book Value Per Share
17.96
|
| Cash Flow |
|
Cash Flow Yield
0.02
|
| Income Statement |
|
Total Revenue
5.44B
|
|
Operating Revenue Per Share
9.91
|
|
Industry Comparison
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
Quotes are at least 15-min delayed:2025/10/24 01:38 EDT
Industry overview quotes are at least 15 minutes delayed
|
Business Description
|
|||
| Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US. |

76.53 
